AnaptysBio Taps Gable PR
Charting the future of public relations
Holmes Report
CEO

AnaptysBio Taps Gable PR

AnaptysBio, a privately-held therapeutic antibody platform and product company, has selected Gable PR to provide public relations and investor communications programs as a part of the company's strategic growth plan for 2009 and beyond.

Paul Holmes

SAN DIEGO—AnaptysBio, a privately-held therapeutic antibody platform and product company, has selected Gable PR to provide public relations and investor communications programs as a part of the company's strategic growth plan for 2009 and beyond.

 

"Gable PR will play a vital role in helping us communicate with key audiences about the advantages of our platform for antibody discovery," says Tom Smart, AnaptysBio chairman and CEO. "We selected Gable PR because of its past successes helping biotech companies with complex messages reach out to broader industry audiences."

 

The program will be managed by Erin Koch, Gable PR director.

 

View Style:

Load 3 More
comments powered by Disqus